Health Condition 1: M430- Spondylolysis
Conditions
Interventions
Intervention1: Nil: Nil
Intervention2: Nil: Nil
Sponsors
Tech clinic connect.
Eligibility
Inclusion criteria
Inclusion criteria: Patients of either sex aged between 30 to 85 years. Diagnosed cases of degenerative spine diseases such as spondylosis (cervical, lumbar, or combined) and/or osteoporosis, confirmed by clinical and radiological findings. Patients who have undergone the ResearchAyu Spineveda Treatment Strategy (STS) between January 2024 and February 2025 at participating centers. Availability of complete baseline and follow-up data in the patient medical records. Patients who had provided written informed consent for treatment and use of anonymized clinical data for research.
Exclusion criteria
Exclusion criteria: Patients below 30 years or above 85 years of age. Patients with infective, inflammatory, or traumatic spine disorders (such as Pott’s spine, ankylosing spondylitis, or fractures). Patients with systemic rheumatoid arthritis, rheumatic heart disease, or autoimmune disorders likely to confound degenerative findings. History of spine surgery, malignancy, or chronic corticosteroid use. Pregnant or lactating women. Patients with incomplete or missing baseline or follow-up data. Patients receiving concurrent Panchakarma or Ayurvedic interventions not part of the STS protocol during the study period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| In our study, time points refer to the scheduled intervals at which outcome assessments will be carried out. All clinical outcomes (including VAS pain score, spinal range of motion, and morning stiffness) will be evaluated at baseline (before initiation of treatment), at 4 weeks, and at 8 weeks. These defined time points will allow comparison of patient outcomes over the treatment duration to assess the effectiveness of the Spinoveda treatment strategy.Timepoint: In our study, time points refer to the scheduled intervals at which outcome assessments will be carried out. All clinical outcomes (including VAS pain score, spinal range of motion, and morning stiffness) will be evaluated at baseline (before initiation of treatment), at 4 weeks, and at 8 weeks. These defined time points will allow comparison of patient outcomes over the treatment duration to assess the effectiveness of the Spinoveda treatment strategy. | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in lumbar spine and femoral bone mineral density (BMD) as recorded in DEXA reportsTimepoint: Baseline and after 6 months of therapy | — |
Countries
India
Contacts
Public ContactDr Kadambari A Tupe
ResearchAyu
Outcome results
None listed